
Feb 27 (Reuters) - Astellas Pharma Inc 4503.T:
PADCEV™ + KEYTRUDA® CUTS RISK OF RECURRENCE OR DEATH BY NEARLY 50% IN CISPLATIN-ELIGIBLE MUSCLE-INVASIVE BLADDER CANCER
ASTELLAS- SAFETY PROFILE FOR PERIOPERATIVE ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB OBSERVED IN EV-304 CONSISTENT WITH PRIOR EXPERIENCE WITH COMBINATION